Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × LY2584702 × Clear all

Phase

Status

Terminated 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1 Neoplasm Metastasis 1

Interventions

Cyclophosphamide 1240 Cisplatin 1182 Radiotherapy 1110 Paclitaxel 1102 Carboplatin 1046 Gemcitabine 1022 Docetaxel 958 Bevacizumab 886 Fluorouracil 745 Doxorubicin 674 Capecitabine 631 Dexamethasone 627 Rituximab 615 Oxaliplatin 584 Etoposide 564 pembrolizumab 556 Irinotecan 531 Filgrastim 530 Cytarabine 489 Leucovorin 482 Nivolumab 460 Vincristine 427 Bortezomib 407 Cetuximab 398 Prednisone 395 Erlotinib Hydrochloride 391 Trastuzumab 390 Surveys and Questionnaires 382 Methotrexate 360 Sorafenib 357

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01241461 2018-08-21

A Study of LY2584702 in Solid Tumors

Eli Lilly and Company

Phase 1 Completed

9 enrolled 9 charts

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡